Tracer library / [225Ac]Ac-mcp-TDI-Y-010
[225Ac]Ac-mcp-TDI-Y-010
Also written as [Ac-225]Ac-mcp-TDI-Y-010
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Radiolabeled monoclonal antibody (anti-DLL3 antibody conjugated to MACROPA-derived chelator, mcp-PEG4-TFP)
- Target / mechanism
- Anti-delta-like ligand 3 (DLL3) monoclonal antibody targeting DLL3-positive neuroendocrine cancer cells PMID 41887735
- Clinical application
- Preclinical radioimmunotherapy for DLL3-expressing neuroendocrine lung and prostate cancer PMID 41887735
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | — | >98% | mcp-PEG4-TFP | 41887735 2026 J Nucl Med All materials and methods used in this study are provided in the supplemental materials |
Need this precursor?We can point you to suppliers for [225Ac]Ac-mcp-TDI-Y-010, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41887735. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41887735: 'TDI-Y-010 was nonspecifically conjugated to mcp-PEG4-TFP and subsequently radiolabeled with 225Ac to synthesize [225Ac]Ac-mcp-TDI-Y-010'.